Stock Report: AVEO Pharmaceuticals Inc. (AVEO) Report Updated: May 13, 2013 | Print This Page

AVEO Pharmaceuticals, Inc., a cancer therapeutics company, engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its lead product candidate, Tivozanib, which in Phase III clinical development stage, is a small molecule oral cancer drug to prevent tumor growth by inhibiting angiogenesis. The company also has a pipeline of monoclonal antibodies, including Ficlatuzumab, a hepatocyte growth factor inhibitory antibody in Phase II clinical development stage for the treatment of non-small cell lung cancer; AV-203, an ERBB3 inhibitory antibody in preclinical development stage for the treatment of solid tumors; and programs directed towards the RON receptor. It has various strategic partnerships with Kyowa Hakko Kirin; Centocor Ortho Biotech Inc.; Astellas Pharma Inc.; Biogen Idec, Inc.; and OSI Pharmaceuticals, Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.